Bafna Pharmaceuticals (BAFNAPH) Q2 25/26 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and half year ended September 30, 2025, following audit committee recommendation.

• Statutory auditors conducted a limited review and found no material misstatements.

Financial highlights

• Revenue from operations for Q2 FY26 was ₹3,546.82 lakhs, down from ₹4,032.31 lakhs in Q2 FY25.

• Net profit for Q2 FY26 stood at ₹312.49 lakhs, up from ₹261.74 lakhs in Q2 FY25.

• Total income for H1 FY26 was ₹7,186.75 lakhs, compared to ₹7,513.71 lakhs in H1 FY25.

• Basic and diluted EPS for Q2 FY26 was ₹1.32, compared to ₹1.11 in Q2 FY25.

Outlook and guidance

• Management continues to focus on core pharmaceutical manufacturing, with no segmental diversification.